[20120317. Complications of EMR/ESD (72): Bleeding (36) - warfarin (4) survey comparing the East and the West]
¸¹Àº °¡À̵å¶óÀο¡µµ ºÒ±¸ÇÏ°í ¿ÍÆĸ° ²÷´Â ¹æ¹ýÀº Àǻ縶´Ù õÂ÷¸¸º°ÀÔ´Ï´Ù. ¹°·Ð °¡À̵å¶óÀÎÀ» ±×´ë·Î Àû¿ëÇϱ⠾î·Á¿î °æ¿ìµµ ÀÖÀ» °ÍÀÔ´Ï´Ù.
µ¿¾ç ÀÇ»ç¿Í ¼¾ç ÀÇ»çÀÇ ³»½Ã°æÀü Ç×ÀÀ°íÁ¦ ¹× Ç×Ç÷¼ÒÆÇÁ¦ Áß´Ü¿¡ ´ëÇÑ ¼º£ÀÌ ¿¬±¸(Lee SY. GIE 2008)°¡ À̸¦ Àß º¸¿©ÁÝ´Ï´Ù.
Questions | Eastern | Western |
I routinely follow the ASGE guideline. | 35.3% | 67.0% |
I perform a biopsy in patients taking warfarin. | 33.7% | 71.2% |
I perform a polypectomy in patients taking aspirin. | 37.5% | 85.6% |
I consider that the risk of bleeding higher in Asians than in other ethnic groups. | 22.4% | 8.1% |
I consider that the risk of thromboembolism is higher in whites than in other ethnic groups. | 39.4% | 21.0% |
ÀϺ»Àΰú ¼¾çÀÎÀÇ ¿ÍÆĸ° metabolismÀº ¾à°£ ´Ù¸£´Ù°í ÇÕ´Ï´Ù (Blood 2004, Pharmacogenet Genomics 2006, Mayo Clin Proc 2009). Àß ¸ð¸£´Â polymorphism °°Àº °Íµµ ÀÖÀ» °ÍÀÔ´Ï´Ù. ÇÏÁö¸¸ ÀúÀÇ Àǹ®Àº ÀÌ°ÍÀÔ´Ï´Ù. "°ú¿¬ metabolism Â÷À̶§¹®¿¡ ³»½Ã°æ practice°¡ ´Þ¶óÁ³À»±î? ¹®ÈÀû, öÇÐÀû Â÷ÀÌ°¡ ±â¿©ÇÑ ºÎºÐÀº ¾øÀ»±î?"
2) Ç×Ç÷¼ÒÆÇÁ¦ Antiplatelets - ³»½Ã°æ ȤÀº Á¶Á÷°Ë»ç Àü ¾Æ½ºÇǸ°, Ç×Ç÷¼ÒÆÇÁ¦¸¦ ²÷À» °ÍÀΰ¡?
3) »õ·Î¿î Ç×ÀÀ°íÁ¦ New oral anticoagulant (NOAC)
4) Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦ Áß´Ü Áöħ (»ï¼º¼¿ïº´¿ø 2011)
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà